Comments on: Junshi Biosciences Announces Ongericimab (anti-PCSK9 mAb) Met Primary Endpoints in Two Phase 3 Clinical Studies //dianhuaminglu.com/en/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e6%98%82%e6%88%88%e7%91%9e%e8%a5%bf%e5%8d%95%e6%8a%97%ef%bc%88%e6%8a%97pcsk9%e5%8d%95%e6%8a%97%ef%bc%89%e7%9a%84%e4%b8%a4%e9%a1%b9iii%e6%9c%9f/ 创新疗法的发现、开发和商业化的生物制药公司?/description> Fri, 17 Mar 2023 06:21:41 +0000 hourly 1 //wordpress.org/?v=6.7.2